
|Articles|October 11, 2012
Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer
Advertisement
In a small, preliminary study, an experimental vaccine provoked a strong immune response against precancerous cells in women treated for cervical lesions that can progress to cancer.
Most cases of cervical cancer are caused by infection with two types of human papillomavirus, or HPV. Some women who have precancerous cervical lesions associated with the Type 16 and Type 18 strains of HPV are able to fight them off without medical intervention. They do so by producing high levels of immune cells called killer T-cells.
Read the full story:
Source: The New York Times
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029
2
FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week
3
Eplontersen Misses Primary End Point in Phase 3 ATTR-CM Cardiovascular Outcomes Trial
4
Impact of Automated Insulin Delivery on Type 2 Diabetes Measures
5




